ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

DCCP Board Okays Concepts For Severn Contract Recompetitions, Denies Two Other

June 19, 1981

NIH to Review Intramural Program: NCI’s Intramural Spending is 17 Percent, Higher than 11.1 Percent NIH-Wide Level

March 7, 2014

HHS Back down, Says Now It Will Support Survey Of Research Facilities

October 28, 1983

University Of Illinois Cancer Center Director Kruh Dies

January 7, 2011

Frist Backs Federal Funding For Stem Cell Research.

July 20, 2001

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003